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1. Introduction 
Lactoferrin is a protein of mammalian origin secreted in the milk of several animals, 
including human beings, cows, horses, pigs, goats and mice (Masson & Heremans, 1971). 
From the moment that bovine (Tomita et al., 2009) and human lactoferrin (Weinberg, 2001) 
were isolated from the milk of their respective species, they began to receive great attention 
due to their multifunctional properties that are distinctive from lactoferrin from other 
mammals. In general, lactoferrin is regarded as a modulator of humoral and cellular 
components involved in inflammatory and immune responses (Actor et al., 2009; Legrand et 
al., 2004), which has broad implications. For instance, lactoferrin displays antimicrobial 
activity against a wide range of pathogens, including virus, bacteria, fungi and parasites 
(Jenssen & Hancock, 2009). It is also able to promote skin integrity by regulating the 
generation of humoral components of the inflammatory and immune responses, including 
such cytokines as the tumor necrosis factor (TNF) alpha  and interleukin (IL) 1beta, as well 
as the migration of Langerhans cells (Kimber et al., 2002). Moreover, lactoferrin enhances 
collagen gel contractile activity of fibroblasts, leading to skin wound healing (Takayama & 
Takezawa, 2006).  
The broad scope of activities of lactoferrin with potential clinical applications, depicted in 
the Table 1, has led to large scale production of native and recombinant preparations of this 
glycoprotein for commercial and/or clinical applications (Drago-Serrano, 2007). Among 
these products are Talactoferrin alfa ®, a recombinant human lactoferrin (Agennix, Houston 
TX, USA), and Bioferrin®, a native lactoferrin from bovine origin (Glanbia, Nutritionals Inc, 
Monroe, WI, USA). Through the modulation of inflammation, Talactoferrin alfa has proven 
effective as a wound healing factor in the experimental model of diabetic mice (Engelmayer 
et al., 2008). Indeed, the promising healing properties of Talactoferrin alfa have been tested 
in a phase 1/2 clinical study for the treatment of ulcers in patients with diabetic 
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ORIGIN ACTIVITY REFERENCE 
 Antibacterial effect  
Bovine Lf ↓ Pseudomonas aeruginosa anti-biofilm formation in 
combination with xilitol (a sugar derivative alcohol) 
(in vitro test) 
Ammons et al., 2011A 
Ammons et al, 2009 
 Phagocytic cell function  
Neutrophil 
human Lf 
↑ Bacterial killing by enhancing reactive oxygen 
species (ROS) generation (in vitro test) 




↓ oxidative effect of ROS released by degranulated 
neutrophils (in vitro test) 
Britigan et al, 1991 
 Anti-Inflammatory effect  
Bovine Lf ↓ Tumor necrosis factor (TNF) production induced 
during bacteremia in mice 
Zimecki et al., 2004 
Human Lf ↓ Lipopolysaccharide (LPS)-induced expression of 
endothelial adhesion molecules (E-selectin, ICAM) 
(in vitro test) 
Baveye et al., 2000A 
 Pro-inflammatory effect   
bLf/hLf ↑ human neutrophil derived interleukin (IL)-8 
production (in vitro test) 




↑ human dendritic cell derived IL-8 production (in 
vitro test) 
Spadaro et al., 2008 
 Granulopoiesis  
Bovine Lf ↑ output of neutrophil precursors in human 
volunteers 
Zimecki et al., 1999B 
Mouse Lf ↑ colony stimulating factor (CSF) in mice Sawatzki & Rich, 1989 
Human Lf ↓ output of granulocyte macrophage progenitor cells 
from spleen and femur of mice 
Gentile & Broxmeyer, 
1983 
 Effects on skin  
Human Lf anti-allergen effect by decreasing Langerhans cell 
migration induced by allergens in humans 
Griffiths et al., 2001  
rHLf ↑ re-epithelialization (in vitro test) 
 
Tang et al., 2010A 
Tang et al., 2010B 
Bovine Lf ↑ gel contractile activity in human fibroblasts (in vitro 
test) 
Takayama et al., 2003 
Bovine Lf ↑ nerve growth factor synthesis/secretion in mouse 
fibroblasts (in vitro test) 
Shinoda et al., 1994 
Bovine Lf ↑ hyaluronan synthesis in human dermal fibroblast 
(in vitro test) 
Saito et al., 2011 
 Wound healing  
(rHLf) Healing enhancement of foot ulcers in diabetic 
mouse model 
Engelmayer et al., 2008 
(rHLf) Healing enhancement of diabetic foot ulcers in 
human patients 
Lyons et al., 2007 
 
Table 1. Overview of multifunctional properties of lactoferrin 
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foot (Lyons et al., 2007). Bioferrin, on the other hand, has been found to have antibacterial 
activity, for which reason it has been used in the control of bacterial infections associated 
with diabetic foot ulcers (Ammons et al., 2011A; Ammons et al., 2009). Such infections 
represent a serious challenge, since they can lead to devastating consequences and possibly 
to limb amputations (Powlson & Coll, 2010). Hence, this glycoprotein is endowed with 
natural antibacterial and wound healing properties that can be beneficial in the treatment of 
either infected or uninfected diabetic foot ulcers. However, given the complex convergence 
of pathologies which encompass diabetic foot syndrome, lactoferrin should not be 
considered as a panacea able by itself to cure this disorder.  
The aim of this chapter is to describe the applications of lactoferrin as an antibacterial and 
wound healing agent. We explore its use as an adjunctive agent to enhance the antibacterial 
activity of antibiotics and/or improve the efficacy of other adjunctive methods of antibiotic 
treatment, the latter of which include growth factors, dressings and other topical 
applications, debridement, and hyperbaric oxygen therapy (O´Meara et al., 2000). In parallel 
we give an overview of the biological and modulating properties of lactoferrin in relation to 
the inflammatory and immune responses, as these properties underlie the reestablishment 
of homeostasis at the dermal level and thus contribute to ulcer skin healing. Finally, we 
discuss the precautions that should be taken into account for the clinical applications of this 
glycoprotein. 
2. Lactoferrin: An overview 
2.1 Structural features 
Lactoferrin is a member of transferrins, a family of proteins with iron chelating properties. 
This monomeric glycoprotein has a molecular weight of 80 kDa, and is highly cationic with 
an isoelectric point of 9.6 (Baker & Baker, 2009). Its tertiary structure consists of two main N 
and C lobes, within which are found the N1/N2 and C1/C2 domains, respectively. The N 
and C lobes are linked at the N1 and C1 domains by a three turn alpha chain (Baker & 
Baker, 2009). Human milk lactoferrin contains two sites of glycosylation (Anderson et al., 
1987) with N-acetylneuraminic acid, N-acetylglucosamine, galactose and mannose (Spik et 
al., 1982).  In spite of the fact that bovine milk lactoferrin has five glycosylation sites, only 
four of them are actually glycosylated (Moore et al., 1997) with N-acetylneuraminic acid, 
galactose, manose, fucose, N-acetylglucosamine and N-acetylgalactosamine (Coddeville et 
al., 1992). Between the N1/N2 and C1/C2 regions, a cleft is formed by R amino acid groups 
of an aspartic, a histidine and two tyrosine residues. At this cleft, iron in ferric form (Fe3+) 
along with the bicarbonate (HCO31-) ion can be bound reversibly to lactoferrin (Anderson et 
al., 1987; Moore et al., 1997). The iron loaded state of lactoferrin is called hololactoferrin, 
while its iron free form is known as apolactoferrin. On the other hand, the N1 domain, 
devoid of any iron chelating activity, has a region known as lactoferricin, which is 
characterized by its strong cationic charge. Lactoferricin can be obtained as a free peptide by 
the enzymatic proteolysis of parental lactoferrin with pepsine. The iron independent 
properties of lactoferrin, such as some forms of antibacterial activity as well as various 
modulating properties of the immune and inflammatory responses, arise from this 
lactoferricin domain (Gifford et al., 2005).  
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2.2 Biological properties  
2.2.1 Distribution 
Lactoferrin is secreted in the milk of several mammals and is regarded as an essential 
component of innate mechanisms of host defense. Evidence of this role is the strategic 
location of lactoferrin at mucosal surfaces, which are frequently colonized and/or invaded 
by pathogenic micro-organisms (Russell et al., 2005). Lactoferrin is also stored in secondary 
(specific) granules of neutrophils, which upon degranulation normally release this 
glycoprotein in serum (Levay &Viljoen, 1995). The extent of neutrophil degranulation and 
the level of lactoferrin in serum increase during an inflammatory response from infectious 
origin (Legrand et al., 2004).  
2.2.2 Effects on cellular components of the adaptive immune response 
As aforementioned, lactoferrin is a modulator of humoral and cellular components involved 
in inflammatory and immune responses. Among its effects on the cellular components of the 
adaptive host defense, lactoferrin  positive or negatively modifies the activity of B 
lymphocytes, T cells, macrophages, dendritic cells, neutrophils, and Langerhans cells 
involved in specific immune responses (Actor et al., 2009). For instance, it is a factor in B 
lymphocyte maturation, a process that defines the phenotype and function of these cells 
(Zimecki et al., 1995). On the other hand, T cell proliferation (Bi et al., 1997) and maturation 
(Zimecki et al., 1991) are enhanced by lactoferrin, evidenced by an increased expression of 
CD4 antigen in the presence of this glycoprotein (Bi et al., 1997; Zimecki et al., 1991; 
Dhennin-Duthille et al., 2000). Other studies show that lactoferrin abrogates the inhibitory 
effect of the iron saturated transferrin on T cell proliferation (Djeha & Brock, 1992), and 
inhibits the proliferative response and cytokine production of Th1 but not Th2, which 
logically affects the activity of Th1/Th2 subpopulations (Zimecki et al., 1996).  
Lactoferrin is also able to modulate macrophages, as antigen presenting cells, to induce a 
Th1 response. That is, in the presence of this glycoprotein, there is an increase of IL 12, 
which in turn is required to combat intracellular pathogens (Wilk et al., 2007). It has been 
reported that lactoferrin expressed on the surface of neutrophils of healthy patients 
interacts with TCD4+ cells to up-regulate the production of IL 10 and down-regulate the 
production of interferon (IFN) gamma. In contrast, in patients with systemic lupus 
erythematosis, lactoferrin expressed on the surface of neutrophils negatively modulated 
the production of IL 10 and IFN gamma by TCD4+ cells.  These results suggest that 
endogenous lactoferrin is able to regulate the expression of interleukins by interacting 
with TCD4+ lymphocytes (Li et al., 2006). Moreover, Lactoferrin acts as a maturation 
factor of antigen presenting cells, such as dendritic  cells (De la Rosa et al., 2008; Spadaro 
et al., 2008) and macrophages (Sorimachi et al., 1997), evidenced by an up-regulated 
expression of CD80/86, the increased priming of T cells, and the enhanced secretion of 
pro-inflammatory mediators such TNF and IL 8.  
The modulatory effects of lactoferrin on cellular components (neutrophils, keratinocytes and 
Langerhans cells) as well as humoral components (cytokines) of the inflammatory response 
involved in the innate mechanisms of bacterial control or dermal homeostasis are addressed 
in section 4 of this chapter. 
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3. Anti-bacterial activity of lactoferrin  
3.1 Importance of iron in infections 
Human beings as well as microorganisms that infect them require iron for living, since this 
metal is necessary for all redox reactions. This transition element is part of the heme group 
in hemoglobin and is a cofactor of enzymes such as ribonucleotide-reductase, indispensable 
for DNA synthesis (Andrews et al., 2003). 
In the body, iron is usually bound to proteins. It is important for the body to maintain a low 
free-iron concentration, as otherwise free iron would lead to the overproduction of reactive 
oxygen species by the Fenton reaction, and these molecules are toxic for proteins, DNA and 
lipids. Moreover, an excessive free-iron concentration would easily be employed by 
invading pathogens for their survival and proliferation. The extracellular iron concentration 
in humans is approximately 10-18 M, a level too low to sustain the growth of microbes trying 
to colonize and invade a host (Bullen et al., 2005; Nairz et al., 2010; Weinberg, 2009). 
Mammals have evolved a general strategy of decreasing the free-iron concentration in order 
to protect themselves against invading microbes. Complex iron-withholding systems are 
based on iron-binding proteins that chelate this ion, such as transferrin that transports and 
delivers iron to all cells, ferritin that stores iron inside the cells in order to avoid its toxicity 
and to maintain cell iron homeostasis (Chiancone et al., 2004), and lactoferrin that, as a 
cationic glycoprotein of the innate immune system, sequesters iron in mucosae and infection 
sites, precisely to avoid the accessibility of iron to all intruders (Bullen et al., 1972, 2005; 
Arnold et al., 1977; Jenssen & Hancock, 2009). Indeed, this was one of the first properties of 
this glycoprotein to be discovered.  
3.2 Bacterial species that infect the diabetic foot 
One major problem caused by pathogenic bacteria to a human host is the constant infection 
suffered by diabetic patients in their inferior extremities. Infected foot ulcers are complex 
interactions of microorganisms that often progress to deeper spaces and tissues. These 
infections can become chronic and incurable, and may even degenerate into septic gangrene, 
which could require foot amputation. Although chronic infections are frequently 
polymicrobial, it has been reported that acute infections in patients not previously treated 
with antibiotics are mainly caused by a single pathogen, usually a Gram-positive coccus 
(Edmonds, 2006; Armstrong & Lipsky, 2004; Powlson & Coll, 2010). Accordingly, early 
surface infections of skin ulcers on the feet of untreated diabetic patients are associated with 
aerobic Gram positive cocci, including Staphylococcus aureus and beta haemolytic 
streptococci group A and B. On the other hand, for diabetic patients with chronic lesions, 
infections are characterized by a polymicrobial mixture of aerobic Gram positive and Gram 
negative bacteria (Escherichia coli, Proteus spp., Klebsiella spp.), anaerobic bacteria (Bacteroides 
spp, Clostridium spp, Peptococcus spp and Peptostreptococcus spp) and Pseudomonas aeruginosa 
(Citron et al., 2007; Dowd et al., 2008).  
Staphylococcus aureus methicillin-resistance strains (MRSA) and Pseudomonas aeruginosa are 
the most prominent components of biofilms, and bacterial biofilm is a major contributor to 
non-healing chronic lesions of diabetic patients. For instance, Pseudomonas aeruginosa is an 
opportunistic pathogen in chronic lesions that is refractory to the killing activity of 
www.intechopen.com
 
Global Perspective on Diabetic Foot Ulcerations 
 
244 
phagocytic cells (e.g., neutrophils), and it is an underlying factor promoting bacterial 
resistance to antibiotics (Guo & DiPietro, 2010). 
Some anaerobes are also responsible for infection in foot ulcers, and even skin commensal 
bacteria may cause damage to tissue (Edmonds, 2006). For mild and severe infections, some 
antibacterials have been shown to be effective in clinical trials, but have numerous side 
effects for patients. Both specific antibiotics as well as those of a wide spectrum have been 
reported to produce distinct side effects, such as nephro- and hepato-toxicity, blood 
dysplasias, diarrhea, and disorders in the commensal flora equilibrium that lead to other 
syndromes by opportunistic microbes (López-Novoa et al., 2011). A very serious problem 
with antibiotic treatments is the emergence of multiresistant strains, generally in long-
standing infections, a result of the fact that the rate of development of new antimicrobial 
drugs is slower than the evolution of resistance. In the case of anaerobes, metronidazole is 
the drug of choice, used together with antibiotics. However, metronidazole is toxic, causing 
nausea, vomiting, abdominal pain and other effects. In addition, it might be carcinogenic to 
patients when used at high doses and/or as a long-term treatment, evidenced by DNA 
breakages and chromosome aberrations caused by this drug in cultured cells, and by its 
carcinogenic effects in animal tests (Roe, 1983; Dobias et al, 1994; El-Nahas & El-Ashmawy, 
2004; Kapoor et al., 1999; Mudry et al., 1994). 
3.3 Lactoferrin as an option in therapy against microbial infections  
Due to the aforementioned problems with antibiotics and other drugs, alternative therapies 
against microbial pathogenic populations have been explored in the last few years. One such 
alternative is lactoferrin, mainly prescribed when infections are chronic and when bacteria 
are found to be resistant to all treatments. Lactoferrin is abundant in colostrum and milk as 
a defense mechanism in newborns. Its iron-free form (apolactoferrin) is secreted by the 
acinar glands to mucosae or by neutrophils in infection sites. This form can be 
microbiostatic, depriving pathogens of iron and thus leaving them in a latent state, or 
microbicidal, leading to the death of pathogens (Jenssen & Hancock, 2009; Ling & Schryvers, 
2006; Yamauchi et al., 2006).  
3.4 Lactoferrin is able to synergize with other proteins and antimicrobials 
3.4.1 Natural synergy of lactoferrin with innate immune-system proteins to combat 
pathogenic microorganisms 
It has been demonstrated that lactoferrin synergizes with other proteins of the innate 
immune system, such as lysozyme and IgA, in order to eliminate microbial infections. 
Indeed, these three proteins are secreted together to mucosae (Leitch & Willcox, 1998; 
Vaerman, 1984). Lactoferrin has large cationic patches on its surface, facilitating direct 
interaction with anionic lipid A from the lipopolysaccharide (LPS) in Gram-negative 
bacteria. This interaction leads to a greater permeability of the outer membrane of such 
bacteria (Jenssen & Hancock, 2009). In the case of Staphylococcus epidermidis, a Gram-positive 
bacterium, it has been proposed that lactoferrin interacts with lipoteicoic acid on the 
bacterial surface, leading to a decrease of the negative charge on the membrane, which in 
turn allows lysozyme to reach the cell wall-associated peptidoglycan where this enzyme acts 
(Leitch & Willcox, 1999A). 
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3.4.2 Lactoferrin also synergizes with drugs and antibiotics, enhancing their 
microbicidal action 
Lactoferrin has the great advantage of synergizing with antiviral and antiparasitic drugs as 
well as with antibiotics, intensifying the antimicrobial activity. In some cases an antibiotic 
dose can be decreased if administered with lactoferrin, which diminishes the side effects to 
patients (Jenssen & Hancock, 2009; Bullen et al., 1972; Arnold et al., 1977; Farnaud & Evans, 
2003; Leon-Sicairos et al., 2006; Sanchez & Watts, 1999; Diarra et al., 2002; Viani et al., 1999). 
Another adjunctive effect of lactoferrin is that biofilms of Staphylococcus epidermidis become 
more susceptible to lysozyme and vancomycin treatment when used in combination with 
this glycoprotein (Leitch & Willcox, 1999B). Interestingly, it was found that lactoferrin 
synergized with bacteriophages (bacterial viruses) in a patient suffering a prolonged 
antibiotic-resistant post-influenza otitis media infection due to Staphylococcus epidermidis, 
and the infection was resolved (Weber-Dabrowsca et al., 2006).  
3.5 Lactoferrin and lactoferricins are able to prevent the formation of biofilms 
Biofilms are a matrix-encased colonial organization of cells that more readily become 
resistant to drugs, antibiotics and antibodies than their free-living, planktonic counterparts. 
This matrix is composed of exopolysaccharide, and its formation is under the control of 
quorum sensing, a bacterial mechanism for assessing population density and altering gene 
expression in order to carry out processes that require the cooperation of a large number of 
cells (Miller & Bassler, 2001). Lactoferrin and its derivative peptides have been used against 
bacteria in biofilms. Furthermore, the synthetic peptides derived from the N-terminal of 
bovine lactoferrin, lactoferricin and lactoferrampin, and a fusion peptide of both, lactoferrin 
chimera, have been assayed against a wide range of pathogens, showing a very high 
probability of success against multiresistant bacteria as well as those accustomed to 
organizing and forming biofilms (Bolscher et al., 2009; Xu et al., 2010; Flores-Villaseñor et al., 
2010). Furthermore, synergistic activity of bovine lactoferricin (11 amino acids) with 
antibiotics was demonstrated against multiresistant clinical isolates of Staphylococcus aureus 
and Pseudomonas aeruginosa in vitro and in a model of corneal infection in mice. Lactoferricin 
also had an anti-inflammatory effect in cornea, suggesting that it leads to a decrease of 
cytokines and mediators involved in inflammation (Oo et al., 2010). Hence, lactoferrin as 
well as its derived peptides could be potential adjuncts to conventional antibiotics in 
combating these pathogens, which also infect diabetic foot ulcers.  
Singh et al. (2002) evaluated the effect of lactoferrin on biofilm development by Pseudomonas 
aeruginosa. In this study, the use of a green fluorescent protein, GFP, as a marker of the 
bacterial cells in continuous-culture allowed for the tracking of biofilm development over 
time. Interestingly, they demonstrated that lactoferrin disrupted biofilm pattern 
development, even at concentrations lower than those needed to kill bacteria or prevent 
their regular growth. By chelating iron, lactoferrin stimulated bacterial twitching, which is a 
specialized surface motility in which bacteria wander across the surface instead of forming 
cell clusters and biofilm. As was hypothesized, this lactoferrin effect was iron-dependent 
and only the iron-free form, apolactoferrin, showed this antimicrobial action. However, 
bacteria in an established biofilm were resistant to lactoferrin.  
Neutrophil derived lactoferrin also was able to prevent bacteria biofilm development of 
Pseudomonas aeruginosa (Leid et al., 2009). Other assays show that lactoferrin in combination 
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with xylitol (a sugar derived penta-hidroxy alcohol) decreases the viability of established 
Pseudomonas aeruginosa, a consequence of both the disruption of the biofilm structure and 
the permeabilization of the bacterial membrane (Ammons et al., 2009).  
3.5.1 Lactoferrin and lactoferricins in the battle against infections associated with 
diabetic foot 
Reproducing diabetic foot in animal models with the aim of studying ulcer infections has 
not proved easy. Nevertheless, an in vitro model of chronic lesion biofilms used to evaluate 
antimicrobial susceptibilities was recently reported. This model imitates the lesion 
environment and allows researchers to study various aspects of the physiology of biofilms, 
as well as the effect of drugs and antibiotics on the same. In this model, pretreatment with 
lactoferrin was employed to test for the inhibition of biofilm development by clinical isolates 
of diverse bacteria species. Results showed that this pretreatment did not affect biofilm 
formation or the number of bacteria, leading the authors to conclude that a continuous 
exposure of biofilm to lactoferrin is necessary in order to achieve this effect, as has been 
suggested in reports by other researchers (Hill et al., 2010). 
In relation to foot ulcers of diabetic patients, there are scant reports about the use of 
lactoferrin. The anti-biofilm efficacy of adjunctive methods, such as silver wound dressings, 
for the therapy of infections associated with chronic ulcers is significantly increased when 
combined with lactoferrin-xylitol. The mechanisms underlying this cooperative 
antimicrobial effect are the iron chelating property of lactoferrin, which destabilizes the 
bacterial membrane, and the inhibitory effect of xylitol on the ability of the bacteria to 
produce siderophores under conditions of iron restriction (Ammons et al., 2011A, 2011B). As 
is well-known, iron deprivation promotes siderophore secretion for acquisition of iron 
essential for bacterial growth (Skaar, 2010). These studies point to the great potential of 
lactoferrin and lactoferricins as an adjunct in the treatment of diabetic foot infections. 
Further studies are needed to explore this potential. 
4. Modulatory activities of lactoferrin on inflammation 
The pleitropic property of lactoferrin spans a wide array of regulatory activities on cellular 
and humoral components of the inflammatory response. The capacity of lactoferrin to 
modulate the inflammatory response has been explored in vitro and in vivo. The animal 
models include the use of exogenous lactoferrin from bovine and human origin (Legrand et 
al., 2004), as well as the observation of untreated animals in order to explore the role of 
endogenous lactoferrin (Legrand & Mazurier, 2010). Here we focus on the regulatory effects 
of lactoferrin on mielopoiesis, the production of cytokines and the generation of reactive 
oxygen species (ROS), and in particular on the inflammatory response in skin allergy and 
skin healing in non-infected lesions.  
4.1 Modulatory effects on ROS generation 
4.1.1 Up-regulation 
Lactoferrin is a key component of immune homeostasis, able to positively or negatively 
regulate the function of cellular components of innate mechanisms of defense involved in 
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inflammation, such as mononuclear cells (monocytes and macrophages) and neutrophils.  
According to in vitro assays with neutrophils treated with bovine lactoferrin, the ability of 
this glycoprotein to enhance phagocytosis may be a result of its direct contact along with an 
opsonin-like action on phagocytic cells (Miyauchi et al., 1998). However, the role of 
lactoferrin in phagocytosis has been linked with its ability to positively regulate the 
generation of ROS with bactericidal activity. Evidence of this up-regulating action is the fact 
that lactoferrin in secondary granules of neutrophils enhances the intracellular killing of 
Pseudomonas aeruginosa by promoting the generation of ROS during phagocytosis (Bullen & 
Armstrong, 1979). It has been reported that exogenous lactoferrin enhances the activity of 
ROS production in neutrophils (Ambruso & Johnston, 1981; Gahr et al., 1991) and 
macrophages (Lima & Kierszenbaum, 1987), and that the presence of iron is necessary for 
this effect to take place (Gahr et al., 1991; Lima & Kierszenbaum, 1987). Hololactoferrin (the 
iron- loaded form) seems to deliver the iron that can act as an enzymatic catalyst  of  Haber-
Weiss reactions, which in turn generate various types of ROS, including hydrogen peroxide 
(H2O2), superoxide anion (O2-) and the hydroxyl radical (OH·) (Actor et al., 2009). Reactive 
oxygen species are substrates for the enzymatic generation of antibacterial molecules. For 
instance, H2O2 is a precursor of hypochlorous (HClO). The latter is a strong bactericidal 
molecule generated enzymatically by mieloperoxidase (MPO) (Hampton et al., 1998), a 
prominent component of azurophil granules in neutrophils (Leffell & Spitznagel, 1974).  
4.1.2 Down-regulation 
Lactoferrin can also have a down-regulatory effect on ROS production, such as is the case 
with phagocytes. The mechanism of this effect is the reduction of oxidative stress and the 
control of an excessive inflammatory response (Actor et al., 2009). During the oxidative 
burst, intracellular generation of ROS is essential for the control of bacterial growth 
(Hampton et al, 1998). However, under conditions of oxidative stress the excessive release of 
ROS to the extracellular milieu has devastating effects on the structure of macromolecules 
and cell functions (Actor et al., 2009). Unlike azurophil granules that store MPO, usually 
associated with phagosomes during bacteria phagocytosis, secondary (specific) granules 
that contain lactoferrin usually become degranulated (Leffell & Spitznagel, 1974). Evidence 
from in vitro assays shows that lactoferrin released during neutrophil degranulation 
decreases the overproduction of ROS (Britigan el al., 1989). Moreover, the uptake of 
exogenous lactoferrin by mononuclear phagocytes that do not contain endogenous 
lactoferrin inhibits their ability to form the hydroxyl radical and protects them from 
membrane auto-peroxidation (Britigan et al., 1991). This effect may be linked to the property 
of lactoferrin to inhibit lipid peroxidation (Gutteridge et al., 1981). In the mouse model of 
pollen induced allergic airway, lactoferrin has been effective in inhibiting the generation of 
the superoxide anion. Pollen grains contain reduced nicotinamide adenine dinucleotide 
phosphate (NADH) oxidases. Their product, O2-, is a precursor of H2O2 and OH·, which 
increase pollen induced airway inflammation (Kruzel et al., 2006). 
Apart from its role in inhibiting the overproduction of ROS by phagocytes, lactoferrin can 
also down-regulate ROS production by neutrophils that are stimulated by LPS. 
Lipopolysaccharide interacts with the soluble receptor lipopolysaccharide binding protein 
(LPB), which in turn enables the binding of LPS to CD14, a membrane receptor of 
phagocytes (Van Amersfoort et al., 2003). After binding to the surface membrane via the 
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LBP/CD14 receptor complex, LPS released by dead or growing bacteria causes neutrophil 
activation, as evidenced by the oxidative burst accompanied with ROS generation. 
Moreover, when LPS is massively released, such as in septic shock, it binds to L-selectin, an 
integral glycoprotein of membrane leukocytes, and this complex also results in the 
production of ROS (Malhotra et al., 1996). Both of these mechanisms of ROS production are 
impeded by the capacity of lactoferrin to bind to LPS (Wang et al., 1995). Additionally, 
lactoferrin blocks the interaction of LPS with the L-selectin of neutrophils, which also avoids 
the production of ROS (Baveye et al., 2000B). It has been shown that either endogenous 
lactoferrin secreted by neutrophils (Wang et al., 1995) or exogenous lactoferrin (Cohen et al., 
1992) can inhibit the ability of LPS to prime neutrophils for enhanced superoxide 
production.  
Interestingly, the IL 10 receptor (IL-10R), a component of secondary granules, also has an 
anti-inflammatory effect, like lactoferrin, in the presence of LPS. This receptor is exported 
from secondary granules to the membrane of neutrophils primed with LPS. When 
interacting with its respective ligand, these IL 10 receptors reduce the production of ROS 
stimulated by LPS (Elbim et al., 2001).  
4.2 Modulatory effects of lactoferrin on pro-inflammatory cytokines 
Lactoferrin is a modulatory agent whose positive or negative effects on cytokine production 
and phagocytes involved in the inflammatory response is highly dependent on the type of 
inductor recognized by the immune system and also on environmental conditions (Actor et 
al., 2009). The modulatory activity of lactoferrin in inflammation has been addressed in 
animal models, such as that of colitis induced by dextran sulfate (Håversen et al., 2003A; 
Togawa et al., 2002) and that of hind-foot inflammation by carrageenan (Zimecki et al., 
1998). This modulatory activity has also been assessed under in vitro and in vivo conditions 
by using LPS as an inducer (Puddu et al., 2010). The proven substantive regulatory effects of 
lactoferrin on inflammation induced by LPS are not fully understood. However, it is known 
that the intrinsic binding properties of lactoferrin to LPS and/or LPS receptors results in an 
interaction with toll like receptor (TLR)-4 and possibly with other unknown receptors, 
leading to the increase (Na et al., 2004) or decrease (Håversen et al., 2002) of cytokine 
production.  
4.2.1 Down-regulation 
The effects of lactoferrin on inflammation have been correlated with a decrease in three pro-
inflammatory mediators: TNF (Håversen et al., 2003A; Togawa et al., 2002; Zimecki et al., 
1998), IL 6 (Togawa et al., 2002; Zimecki et al., 1998) and IL 1 (Togawa et al., 2002). These 
effects have also been associated, in some cases, with an increase in two anti-inflammatory 
interleukins: IL 4 and IL 10 (Togawa et al., 2002). In animal models of infection with Shigella 
flexneri (Gómez et al., 2002), Salmonella typhimurium (Mosquito et al., 2010) and Lysteria 
monocytogenes (Lee et al., 2005), lactoferrin  from bovine or human origin has been  effective 
in reducing inflammatory necrosis in liver (Lee et al.,  2005) and intestine (Mosquito et al., 
2010), as well as in intestinal edema (Gomez et al., 2002). Owing to its anti-inflammatory 
effect, as evidenced by the reduced levels of TNF (Lee et al., 2005; Komine, et al., 2006; 
Zimecki et al., 2004) and IL 6 (Håversen et al., 2003B), lactoferrin contributes to a decrease in 
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tissue damage caused by the inflammation induced by bacterial pathogens. Other assays 
also have shown that lactoferrin released by phagocytes acts as a negative feedback factor 
by decreasing the TNF released from these cells, which in turn prevents their excessive 
recruitment and activation of phagocytes. In this way, lactoferrin modulates the recruitment 
to sites of inflammation (Crouch et al., 1992).  
There is also evidence that lactoferrin increases the expression of LFA-1, an adhesion 
molecule of blood mononuclear cells (Zimecki et al., 1999A). This is another molecule 
involved in the migration of phagocytes to inflammatory sites. On the other hand, 
lactoferrin inhibits LPS-induced expression of two adhesion molecules, E-selectin and 
ICAM-1, by endothelial cells (Baveye et al., 2000A). Furthermore, it decreases the IL 8 
production induced by LPS and competes with this chemokine for its binding to 
proteoglycans of endothelial cells (Elass et al., 2002).  
4.2.2 Up-regulation 
In addition to its role as a down-regulator of some pro-inflammatory cytokines, lactoferrin 
has also been found to stimulate the production of other pro-inflammatory cytokines 
associated with resistance to bacteria. For instance, the activation by lactoferrin of 
mononuclear cells and polymorphonuclear leukocytes has been correlated with its ability to 
stimulate the release of IL 8 (Spadaro et al., 2008; Sorimachi et al., 1997; Shinoda et al., 1996). 
Up-regulatory properties of lactoferrin on TNF levels increase the efficacy of the BCG 
vaccine by inducing the increase of pro-inflammatory cytokines like IL 6 and IFN gamma, 
involved in the resistance against Mycobacterium tuberculosis (Hwang et al., 2007). In 
transgenic mice carrying a functional human Lf gene and infected with Staphylococcus aureus, 
causing septic arthritis, the increase of a pro-inflammatory Th1 response due to greater TNF 
and IFN gamma levels (and a decreased Th2 response of anti-inflammatory mediators IL 5 
and IL 10) was associated with a reduced incidence of arthritis and mortality (Guillén et al., 
2002). Thus, the pro-inflammatory effects of lactoferrin contribute to resistance to infections 
caused by the aforementioned pathogens. 
4.3 Modulatory effects on mielopoiesis 
Another protective effect of bovine lactoferrin in the protection against Escherichia coli 
bacteremia in mice has been associated with an increased turnover of neutrophils (Zimecki 
et al., 2004). In this regard, the demand for neutrophils greatly increases in the inflammatory 
response caused by infections. Thus, the effect of lactoferrin on bacterial resistance may be 
linked to its regulatory properties on cytokines involved in mielopoiesis, including IL 1,IL 6, 
IL 8 and TNF, as well as on mielopoietic  growth factors, such as granulocyte macrophage 
colony stimulating factor (GM-CSF), G-CSF and M-CSF (Artym & Zimecki, 2007). These 
soluble factors favor mielopoiesis, i.e., the process of the generation of granulocyte and 
monocyte leukocytes from a bone marrow pluripotent cell.  
The modulatory activity on mielopoiesis has been described in relation to lactoferrin 
released by human neutrophils and exogenous lactoferrin tested with culture cells or 
administered to animals or human volunteers (Artym & Zimecki, 2007). The modulatory 
role of lactoferrin upon progenitor cells of the granulocyte/macrophage lineage has been 
controversial (Artym & Zimecki, 2007). In healthy humans orally treated with bovine 
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lactoferrin, the up-regulatory action of lactoferrin on granulopoiesis was linked to the 
increased output of neutrophil precursors along with an attenuated release of TNF and IL-6 
(Zimecki et al., 1999B). The effect of lactoferrin in promoting granulopoiesis apparently 
results from its ability to stimulate the increase in CSF production, as was shown under in 
vitro and in vivo conditions (Sawatzki & Rich, 1989). With assays of mouse bone marrow and 
peritoneal cells, both cultured with or without indomethacin (a non-steroidal anti-
inflammatory drug used as an inhibitor of prostaglandin synthesis), mouse or human 
lactoferrin promoted an increase in CSF. On the other hand, injection of mice with endotoxin 
free mouse lactoferrin stimulated an early increase in CSF production, and a more delayed 
increase in bone marrow granulocyte macrophage progenitor cells (GM-CFC) (Sawatzki & 
Rich, 1989).  
Lactoferrin also can have a negative effect on mielopoiesis, as evidenced by the iron 
dependent capacity of human lactoferrin to suppress the number of granulocyte 
macrophage progenitor cells from femur and spleen of mice (Gentile & Broxmeyer, 1983). 
This iron dependent suppressor effect of human lactoferrin, when tested in human bone 
marrow derived cells and blood monocytes, was linked to the decrease of GM-CSF 
(Broxmeyer et al., 1980). However, the role of lactoferrin as a modulating agent on 
granulopoiesis was not at all confirmed by some other studies (DelForge et al., 1985; Winton 
et al., 1981).  
These divergent results in regard to the modulatory effects of lactoferrin on leukocyte 
generation have probably arisen from variations in experimental design. After all, the 
inflammatory response is a very complex spatio-temporal process of multiple steps. The 
effect of lactoferrin on mielopoiesis must therefore be dependent on the stage of the 
inflammatory response. Lactoferrin as an immunoregulatory protein should presumable act 
first by enhancing the inflammatory response, and later by suppressing the same (Artym & 
Zimecki, 2007). 
4.4 Modulatory effects of lactoferrin on inflammation in models of skin allergy and 
skin wound healing 
The skin is the largest organ of the human body, made up of three main layers: epidermis, 
dermis and the hypodermis (Kanitakis, 2002). The epidermis layer contains no blood 
vessels and is made up of 90-95 % keratinocytes and 5% Langerhans cells, melanocytes 
and Merkel cells. Keratinocytes, upon dying due to a lack of blood supply, are responsible 
for skin keratinization by releasing keratin to extracellular surroundings. Langerhans cells 
are mobile dendritic presenting cells derived from CD34+ bone marrow precursor cells. 
Melanocytes produce melanin, a natural dye to protect skin from ultraviolet radiation. 
Merkel cells display neuroendocrine and epithelial features and function  
as mechanoreceptors by their contact through synaptic junctions with dermal sensory 
axons.  
The dermis, the second layer of the skin, is tightly connected to epidermis by a basement 
membrane which protects the latter layer from stress. The dermis is a vascularized layer 
formed by an elastic and compressible connective tissue that contains fibroblasts, dermal 
dendrocytes (mesenchymal dendritic cells), mast cells and a dense network of collagen 
fibers.  
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The hypodermis represents the inner layer of skin and is made up of loose connective tissue 
and elastin. The main types of cells present in this layer are fibroblasts, macrophages and 
adipocytes. This layer contains 50% body fat and plays a relevant role in thermoregulation, 
insulation and supply of energy. It also acts as a shield against mechanical injuries 
(Kanitakis, 2002). 
Lactoferrin displays a role in skin homeostasis by its ability to positively or negatively 
modulate the generation cytokines derived from keratinocytes and Langerhans cells, with 
an essential role in immune and inflammatory responses (Wang et al., 1999).  
4.4.1 Modulation of the inflammatory response associated with skin allergy 
Trials with human volunteers and assays on mice have addressed down-regulatory 
properties of bovine or human lactoferrin on pro-inflammatory cytokines generated during 
dermal allergic responses induced by diphenylcyclopropenone (DPC) (Griffiths et al., 2001; 
Kimber et al., 2002) and oxazolone (Cumberbatch et al., 2000).  
In models of skin allergy induced by DPC or oxazolone, epidermal Langerhans cells migrate 
to skin-draining lymph nodes. As a consequence, there is an accumulation and maturation 
of Langerhans cells as dendritic cells able to perform their antigen presentation role to naïve 
T cells (Wang et al., 1999). In the aforementioned models of skin allergy, the migration of 
Langerhans cells depends on the local production by skin keratinocytes of IL 1beta, which in 
turn is dependent on de novo production of TNFalpha. In humans, TNF alpha stimulates the 
activation and migration of Langerhans cells from the dermis, and their subsequent 
accumulation in human skin-draining lymph nodes (Cumbertbach et al., 1999). This 
cytokine also promotes the migration of immature Langerhans cells to human lymph nodes 
involved in chronic skin inflammation (Geissmann et al., 2002). In this regard, the anti-
inflammatory property of lactoferrin applied topically to humans and mice has been linked 
to a decrease in the migration of skin Langerhans cells induced by DPC or oxazolone 
(Griffiths et al., 2001; Kimber et al., 2002; Cumberbatch et al., 2000). As in the case of DPC or 
oxazonolone, homolog lactoferrin inhibits the mobilization of Langerhans cells induced by 
intradermic IL 1beta in humans (Cumberbatch et al., 2003) and mice (Cumberbatch et al., 
2000). However, in mice, homolog lactoferrin fails to reduce the migration of Langerhans 
cells induced by the application of exogenous TNF alpha (Cumberbatch et al., 2000). It 
seems that the down-regulatory effect of lactoferrin on Langerhans cell migration induced 
by DPC or oxazolone allergens, occurs after inhibiting de novo synthesis of TNF alpha by 
epidermal keratinocytes.  
Another down-regulatory effect of bovine lactoferrin has also been described in the mouse 
model of zymosan-ear skin inflammation (Hartog et al., 2007). In this model, bovine 
lactoferrin had an anti-inflammatory effect by suppressing local production of TNF alpha. 
Furthermore, a combination of lactoferrin and glycine generated a synergistic anti-
inflammatory effect (Hartog et al., 2007). 
In patients with eczematous dermatitis caused by contacting nickel, recombinant human 
lactoferrin decreased the inflammatory response by inhibiting type 1 and type 2 T cell 
responses. In that study lactoferrin suppressed T cell proliferation and inhibited the 
expression of chemokine receptors CCR10, CXCR3 (expressed on Th1) and CCR4 (expressed 
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on Th2 cells). However, the production of IFN gamma by Th1 and IL 5 by Th2 was partially 
suppressed by lactoferrin (Moed et al., 2004).  
4.4.2 Effect of lactoferrin on cutaneous homeostasis and skin wound healing 
4.4.2.1 Stages of skin wound healing 
Some of the humoral and cellular components of the inflammatory and immune responses 
that are modulated by lactoferrin in turn regulate mechanisms with an essential role in 
cutaneous homeostasis and wound healing. As is known, dermal wound healing is a normal 
process of repair that involves four continuous, overlapping and precisely programmed 
stages: i) hemostasis ii) inflammation, iii) fibroplasia, and iv) remodeling (Hardy, 1989; Guo 
& DiPietro, 2010).  
Hemostasis results from vasoconstriction and clotting by fibrin deposition to control 
bleeding caused by the vascular injury. The clot along with injured surrounding tissue 
release pro-inflammatory mediators and growth cell factors, such as transforming growth 
factor (TGF) beta1, fibroblast growth factor (FGF) and epidermal growth factor (EGF) (Guo 
& DiPietro, 2010).  
In the inflammatory phase, sequential infiltration of neutrophils, macrophages and 
lymphocytes occurs in damaged tissue. The presence of phagocytes is mandatory for 
bacterial and cellular debris clearance (Hardy, 1989). The pro-inflammatory contribution of 
lactoferrin in this stage may be linked to its ability to up-regulate the bactericidal activity of 
neutrophils (Ambruso & Johnston, 1981; Gahr et al., 1991) and macrophages (Lima & 
Kierszenbaum, 1987) aimed at the control of bacterial growth. During this stage, lactoferrin 
also modulates the overproduction of ROS released during neutrophil degranulation in 
order to protect the organism from toxic effects of the same (Britigan el al., 1989).  
In the early inflammatory phase, TNF alpha has an essential role in wound healing. 
However, since its overproduction can cause tissue damage, the fact that lactoferrin 
decreases TNF released from phagocytes may contribute to preventing the excessive 
recruitment and activation of phagocytes to sites of inflammation (Crouch et al., 1992). 
Evidence from in vitro cultures of peripheral and bone marrow monocytes of human origin 
suggest that the down-regulating effects of lactoferrin on inflammation may also be linked 
to its suppression of the release of IL 1 from monocytes. This in turn decreases GM-CSF 
production by fibroblasts (Zucali et al., 1989), which may contribute to controlling the 
mobilization of peripheral blood cells to inflammatory sites.   
The fibroplastic phase is characterized by three processes: i) re-epithelialization, ii) wound 
contraction and iii) production of extracellular matrix components such as collagen (Hardy, 
1989). Numerous subtypes of keratinocytes (Patel et al., 2006) and fibroblasts (El Ghalbzouri et 
al., 2004) play an essential role in scar tissue formation by contributing to wound re-
epithelialization. In the early response to injury, re-epithelialization occurs when fibroblasts in 
the neighborhood of the wound proliferate and then migrate to the wound bed, where they 
are induced by chemotactic mediators to produce extracellular matrix components (Hardy, 
1989). Among these components are proteoglycans (heparan-, chondroitin- and keratan-
sulfate), non-proteoglycan polysaccharide (hyalouronic acid) and fibers (collagen, elastin) 
(Labat-Robert et al., 1990). Dermal healing is accompanied by a process of granulation, which 
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results from the accumulation of fibroblasts and extracellular matrix components along with 
the formation of new blood vessels to constitute granular tissue (Hardy, 1989).   
Generation of granular tissue is a complex process regulated by cytokines such as TGF beta1 
produced by keratinocytes, macrophages and fibroblasts (Werner et al., 2007). Transforming 
growth factor beta1 stimulates the expression of integrins in keratinocytes, which facilitates 
their migration to perform the re-epithelialization during wound healing (Gailit et al., 1994). 
Granulation is also dependent on growth factors such as EGF, platelet derived growth factor 
(PDGF) and basic fibroblast growth factor (bFGF) (Werner et al., 2007).  In vitro assays show 
that TGF beta1 and PDGF regulate fibroblast attachment, which represents the step between 
cell migration and proliferation in vivo during wound healing (Ihn et al., 1995). Additionally, 
TGF beta1, bFGF and other blood derived factors promote cell migration and proliferation 
leading to the increase of cells in the denuded area, or wound space (Schreier et al., 1993). 
Other agents that exercise healing effects, by enhancing migration and proliferation of 
keratinocytes for re-epithelializing of the wound bed, include keratinocyte growth factor 2 
(Soler et al., 1999), heparin binding EGF like growth factor (Shirakata et al., 2005), skin beta-
defensins (Niyonsaba et al., 2007) and insulin (Liu et al., 2009). 
4.4.2.2 Effects of lactoferrin on wound healing  
The role of lactoferrin in the fibroplastic phase has been addressed in some in vitro cultures 
of human skin fibroblasts (Tang et al., 2010A) and keratinocytes (Tang et al., 2010B). These 
assays show that recombinant human lactoferrin sustains the survival of fibroblasts and 
keratinocytes by protecting them from apoptosis, and in this way enhances re-
epithelialization by stimulating the proliferation and migration of these cells.  
It has been reported that bovine lactoferrin is also able to enhance collagen gel-contractile 
activity in human fibroblasts, which is the in vitro model for the reorganization of the 
collagen matrix during the wound healing process. Gel contractile activity induced by 
bovine lactoferrin is accompanied by the activation of extracellular regulated kinase (ERK) 
1/2 and myosin light chain kinase (MLCK), and the subsequent elevation of myosin light 
chain phosphorylation. The effects of lactoferrin on gel contractile activity and its signaling 
pathway were mediated by the low density lipoprotein receptor related protein (LRP) 
(Takayama et al., 2003).  
Lactoferrin may contribute to wound healing in the fibroplastic stage by its promotion of the 
synthesis and secretion of the nerve growth factor, which was observed in one study during 
the contact of bovine lactoferrin with mouse fibroblasts (Shinoda et al., 1994). The nerve 
growth factor (NGF) is an angiogenic agent with healing activity on diabetic skin ulcers in 
humans (Aloe, 2004) and mice (Graiani et al., 2004). Also in the fibroplastic stage, lactoferrin 
promotes the synthesis of components of extracellular matrix, such as type 1 collagen and 
hyaluronan, the latter through the activation of the TFG beta1 signaling pathway. This has 
been shown in vitro with assays on human fibroblasts (Saito et al., 2011). 
5. Applications of lactoferrin as an adjunctive agent in the treatment of 
infections associated with diabetic foot ulcers   
Whereas the previous discussion demonstrates that lactoferrin possesses pleitotropic 
properties on cell components involved in the inflammation associated with skin allergy or 
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skin reparation of non-infected surface wounds, what follows is intended to describe 
potential applications of lactoferrin as an adjunctive agent to control bacterial growth in 
infected foot ulcers, which can threaten a limb or even the life of diabetic patients. Diabetic 
foot syndrome encompasses a complex convergence of pathologies, including diabetic 
neuropathy, peripheral vascular disease, Charcot´s neuroarthropathy, and osteomyelitis and 
foot ulceration. Diabetic foot ulcers are usually detected at the plantar surface and result 
from neuropathy, inadequate blood supply (ischemia) (Khanolkar et al., 2008), hypoxia 
(Tamir, 2007) and disturbances in neutrophil phagocytic function (Bader, 2008). Neuropathy 
plays a major role in foot ulceration since it underlies the loss of limb sensibility to skin pain 
caused by dermal abrasions and blisters, owing to disturbances of sensory, motor and 
autonomic functions (Khanolkar et al., 2008). 
At present, the evaluation of lactoferrin as an agent with wound healing properties has been 
limited to only two studies: an experimental study on diabetic mice (Engelmeyer et al., 2008) 
and a clinical study on patients (Lyons et al., 2007). In the former, topically applied 
Talactoferrin, versus the vehicle or becaplermin (a recombinant human platelet-derived 
growth factor), increased the closure rate. In vitro culture assays suggest that the underlying 
mechanism of the healing effect of Talactoferrin on mouse diabetic ulcers could be linked 
with its ability to enhance the migration of dermal fibroblasts, THP-1 macrophages, Jurkat T 
cells and mouse granulocytes. Other activities of Talactoferrin associated with its healing 
properties include its ability to enhance the production of IL-8, IL-6, MIP-1 alpha and TNF 
, all of which have an essential role in the early inflammatory phase of wound healing 
(Engelmayer et al., 2008).   
In the clinical study, Talactoferrin was delivered topically in gel to the non-healing chronic 
ulcers from fifty five diabetic patients (patients with any sign of osteomyelitis, gangrene o 
deep tissue infection were excluded). The first phase, an open label, sequential, dose-
escalation study, evaluated the safety of Talactoferrin. Groups of patients were treated with 
1% (n=3), 2.5% (n=3) or 8.5% (n=3) of Talactoferrin gel applied topically at the ulcer twice 
daily for 30 days in combination with standard wound care. No adverse effects were 
detected. The second phase assessed the efficacy of two distinct doses of Talactoferrin. This 
was a single blind randomized, stratified placebo controlled pilot study of three groups of 
patients treated with gel containing 2.5% (n=15) and 8.5% (n=15) of Talactoferrin gel or 
placebo gel (n=16). In combination with standard wound care, Talactoferrin gel was 
administered topically twice daily to the ulcers for 12 weeks. The results from the second 
phase showed that Talactoferrin was effective as a healing agent, evidenced by a significant 
difference (P<0.01) between the results in the Tlactoferrin-treated and control groups. The 
incidence in the reduction of the size of ulcers in the groups treated with 2.5% and 8.5 % 
Talactoferrin gel was ≥ 75% compared with 45%-25% in the groups treated with placebo gel. 
Accordingly, Talactoferrin has been shown to be an effective agent with healing properties 
and seems to be pharmacologically safe and well tolerated. Thus, it may be useful in the 
treatment of foot ulcers in diabetic patients (Lyons et al., 2007).  
Due to the multifactorial characteristic of the diabetic foot syndrome, lactoferrin does not 
fulfill the therapeutic requirements for use as a single healing agent. However, some 
standard techniques of un-infected and un-ischemic diabetic ulcers like debridement (i.e., 
removal of unhealthy tissue from the wound bed) (Tamir, 2007) may be improved by 
including lactoferrin as an adjunctive therapeutic agent.  
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Some pharmaceutical formulations of lactoferrin, including liposomes administered intra-
articularly in joints (Trif et al., 2001) or by oral route (Ishikado et al., 2005) to control the 
chronic inflammation of arthritis or other pathologies, as well as bioadhesive tablets 
administered to treat inflammation associated with oral ulcers (Takahashi et al., 2007; 
Takeda et al., 2007), may represent systemic or oral delivery formulations for adjunctive 
treatment of chronic wounds. As is known, a prolonged inflammatory response is a 
contributing factor of chronic wounds, since it abrogates the normal process of ulcer healing 
(Pierce, 2001).    
Diabetic patients usually suffer skin dryness, which prompts injuries that are highly 
susceptible to bacterial infections. When foot skin of the plantar surface is injured, 
microorganisms that are normally retained gain access to underlying layers where bacterial 
replication leads to local and/or systemic infections (Guo & DiPietro, 2010). Bacterial 
infections associated with chronic non-healing foot ulcerations, apart from being a common 
cause of limb amputation, put the life of the diabetic patient at risk (Bader, 2008).  
The effectiveness of standard methods of care, including off-loading, debridement, systemic 
and local antibiotics and topical antiseptics, can be substantially improved when combined 
with adjunctive techniques. In some cases, adjuncts like wound dressings (Hilton et al., 
2004), hyperbaric oxygen and growth factors are needed to provide better conditions for 
closure. Such conditions include a moist environment to enhance an optimal inflammatory 
milieu, as well as an adequate supply of oxygen and nutritional factors (Hopf et al., 2001).  
Silver wound dressings have been applied to control the formation of biofilms associated with 
acute and chronic ulcers in diabetic patients (Hilton et al., 2004). However, as the treatment 
progresses, the single antibacterial effect of the silver is surpassed by the generation of 
antibacterial resistance caused by the establishment of bacterial biofilms which in turn impede 
healing of chronic ulcers in diabetic patients. Lactoferrin may be included in the list of adjuncts 
with a role in the establishment of the proper conditions for the healing of the wound bed, 
owing to its aforementioned natural antibacterial and wound healing properties. In this 
regard, a pharmaceutical presentation of lactoferrin and xylitol in hydrogel proved effective in 
enhancing the antibiofilm efficacy of a commercial silver wound dressing (Ammons et al., 
2011B). That study showed that the combination of lactoferrin, xylitol and silver provides 
significant antimicrobial efficacy against established biofilms formed by methicillin-resistant 
Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Consequently, lactoferrin in 
combination with xylitol would be recommended to increase the antibacterial effect of silver 
wound dressings applied to infected wounds of diabetic patients.  
Thus, wound healing and anti-biofilm properties enable lactoferrin, acting as an adjunctive 
agent, to enhance the efficacy of anti-biofilm targeted techniques for the treatment of 
infected chronic ulcers like silver wound dressings.   
6. Safety measures in the use of Lactoferrin  
Toxicological assays on rats chronically treated by the oral route with human recombinant 
(Cerven et al., 2008; Appel et al, 2006) or native bovine (Yamauchi et al., 2000) lactoferrin 
show that regardless of their origin, these proteins are pharmacological safe products. In 
spite of their free toxicity status, some concerns have been raised, including bacterial 
resistance to human lactoferrin, as in the case of Streptococcus pneumoniae (Hammerschmidt 
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et al., 1999), and the autoimmune potential of cross reactive anti-lactoferrin antibodies which 
recognize bacterial antigens like the 65 kDa protein of Mycobacterium tuberculosis (Esaguy et 
al., 1991). Although neither Streptococcus pneumoniae or Mycobacterium tuberculosis are 
associated with infections in diabetic foot ulcers, bacterial resistance and the autoimmune 
potential of cross reactive anti-lactoferrin antibodies warn of the need to be alert to possible 
problems in the application of lactoferrin as an antibacterial agent. While this requires 
attention to side effects that could present themselves, it does not in any way undermine all 
of the positive results of lactoferrin found to date.  
The pathological relevance of anti-lactoferrin autoantibodies remains uncertain (Audrain et 
al., 1996). However, it is possible that in some chronic degenerative diseases such as 
rheumatoid arthritis (Esaguy et al., 1993), ulcerative colitis, primary sclerosing cholangitis 
and Crohn´s disease, autoantibodies to lactoferrin may aggravate and sustain the 
inflammatory condition (Peen et al., 1993).  
Host-produced lactoferrin has been associated with some degenerative diseases and 
therefore the administration of exogenous lactoferrin may aggravate and contribute to the 
multifunctional pathology of diabetic foot syndrome. In this regard, endogenous lactoferrin 
has been reported as a major component of amyloid depots in patients with gelatinous 
drop-like corneal dystrophy (Klinworth et al., 1997), and it has been detected in pathological 
lesions in a variety of neurodegenerative disorders as Alzheimer´s disease, amyotrophic 
lateral sclerosis/parkinsonism dementia complex of Guam and sporadic amyotrophic lateral 
sclerosis, or Pick´s disease (Leveugle et al., 1994).  
On the other hand, in some sensitized individuals, lactoferrin from bovine milk can be a strong 
milk allergen (Gaudin et al., 2008). Therefore in such individuals with diabetic foot, the 
allergenic potential of bovine lactoferrin should be taken into account before prescribing its 
oral administration. Additionally, the undesirable pro-inflammatory effects of iron loaded 
lactoferrin on vascular permeability, as evidenced in the dermis of rats by the increase of 
albumin extravasation (Erga et al., 2001), could negatively affect the process of skin healing.  
7. Conclusion  
The antibacterial and wound healing properties of lactoferrin may contribute to enhancing 
the effectiveness of standard techniques for treatment of infections of diabetic foot ulcers. 
Futures studies are needed to address the substantive therapeutic contribution of lactoferrin 
as an adjunctive agent in the treatment of infections associated with diabetic ulcer, including 
the concerns and limitations of its application.  
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